GlassScriptPhysician profile
Lore B Wootton
NPI 1649365404
$2,905.20
in general payments reported to CMS, 2019-2025
33 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $234 · 2021: $521 · 2022: $581 · 2023: $373 · 2024: $444 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $479.75 | 2019-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $308.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Grifols USA, LLC | $234.19 | 2021-2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $204.35 | 2019-2024 | Yupelri |
| Pfizer INC. | $188.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $170.45 | 2020-2024 | Farxiga |
| Abbvie INC. | $161.65 | 2021-2025 | Qulipta |
| Astellas Pharma US INC | $123.24 | 2020-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $112.42 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $107.87 | 2019-2022 | |
| Exact Sciences Corporation | $95.14 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Radius Health, INC. | $79.34 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $75.92 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.51 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $62.96 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $51.90 | 2022-2023 | Hetlioz, Fanapt |
| Allergan, INC. | $48.90 | 2019-2020 | |
| Lilly USA, LLC | $42.87 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $37.10 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $36.45 | 2021 | |
| Stryker Corporation | $26.69 | 2024 | Triathlon |
| Alnylam Pharmaceuticals INC. | $23.07 | 2023 | Amvuttra |
| Abbott Laboratories | $22.39 | 2025 | Freestyle Libre 3 |
| Organon LLC | $18.49 | 2022 | |
| Viatris Specialty LLC | $16.75 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.09 | 2021 | |
| Lundbeck LLC | $14.89 | 2024 | Rexulti |
| Horizon Therapeutics Plc | $14.81 | 2020 | |
| Boston Scientific Corporation | $14.30 | 2025 | General - Pain Management |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.41 | 2022 | |
| Gilead Sciences, INC. | $13.04 | 2023 | |
| Lucid Diagnostics INC. | $12.80 | 2022 | |
| Merck Sharp & Dohme LLC | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lore Wootton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.